<p>Y Intercept Hong Kong Ltd 在第二季度根据其最新的 13F 文件向证券交易委员会报告，购买了 Celldex Therapeutics, Inc.（NASDAQ:CLDX - 免费报告）的新股份。该基金购买了 58,398 股生物制药公司的股票，价值约为 1,188,000 美元。Y Intercept Hong Kong Ltd 在最近一个季度末持有 Celldex Therapeutics 约 0.09% 的股份。</p>
<p>获取 <strong>Celldex Therapeutics</strong> 的提醒：</p>
<p>其他一些机构投资者也增加或减少了对该公司的持股。Envestnet Asset Management Inc. 在第二季度收购了价值 861,000 美元的 Celldex Therapeutics 新股份。Nisa Investment Advisors LLC 在第二季度将其在 Celldex Therapeutics 的持股增加了 171.7%。Nisa Investment Advisors LLC 现在拥有 1,394 股生物制药公司的股票，价值 28,000 美元，此前在上个季度购买了额外的 881 股。AlphaQuest LLC 在第二季度将其在 Celldex Therapeutics 的持股增加了 7.0%。AlphaQuest LLC 现在拥有 12,956 股生物制药公司的股票，价值 264,000 美元，此前在上个季度购买了额外的 844 股。TD Asset Management Inc 在第二季度将其在 Celldex Therapeutics 的持股增加了 62.1%。TD Asset Management Inc 现在拥有 127,878 股生物制药公司的股票，价值 2,602,000 美元，此前在上个季度购买了额外的 49,000 股。最后，Sovran Advisors LLC 在第二季度购买了价值约 842,000 美元的 Celldex Therapeutics 新股份。</p>
<h2>分析师设定新目标价</h2>
<p>一些券商最近对 CLDX 发布了报告。巴克莱在 10 月 13 日星期一的研究报告中对 Celldex Therapeutics 的股票进行了覆盖，给予了 &#34;减持&#34; 评级和 25.00 美元的目标价。HC Wainwright 在 8 月 20 日星期三的报告中将 Celldex Therapeutics 的目标价从 50.00 美元下调至 42.00 美元，并给予了 &#34;买入&#34; 评级。花旗在 8 月 20 日星期三的报告中将 Celldex Therapeutics 的目标价从 56.00 美元下调至 48.00 美元，并给予了 &#34;买入&#34; 评级。Weiss Ratings 在 10 月 8 日星期三的研究报告中重申了对 Celldex Therapeutics 的 &#34;卖出（d-）&#34; 评级。最后，富国银行在 8 月 20 日星期三的研究报告中将 Celldex Therapeutics 的目标价从 44.00 美元下调至 38.00 美元，并给予了 &#34;增持&#34; 评级。一位股票研究分析师对该股票给予了强烈买入评级，七位分析师给予了买入评级，一位分析师给予了持有评级，两位分析师给予了卖出评级。根据 MarketBeat.com 的数据，该股票的共识评级为 &#34;适度买入&#34;，平均目标价为 44.20 美元。</p>
<p><strong>查看我们对 CLDX 的最新分析</strong></p>
<h2>Celldex Therapeutics 股票下跌 7.4%</h2>
<p>CLDX 的股票在星期二开盘价为 24.75 美元。Celldex Therapeutics, Inc. 的 12 个月低点为 14.40 美元，12 个月高点为 29.05 美元。该公司的 50 天移动平均线为 25.32 美元，200 天移动平均线为 22.62 美元。该股票的市值为 16.4 亿美元，市盈率为 -8.22，贝塔值为 1.33。</p>
<p>Celldex Therapeutics（NASDAQ:CLDX - 获取免费报告）最近在 8 月 7 日星期四发布了其财报。这家生物制药公司报告的每股收益（EPS）为 -0.85 美元，超过了分析师的共识预期（-0.86 美元）0.01 美元。该公司在本季度的收入为 73 万美元，而分析师的预期为 113 万美元。Celldex Therapeutics 的股本回报率为 -27.61%，净利润率为 -3,446.88%。分析师预计 Celldex Therapeutics, Inc. 在本年度将发布 -2.48 的每股收益。</p>
<h2>关于 Celldex Therapeutics</h2>
<p>（免费报告）</p>
<p>Celldex Therapeutics, Inc. 是一家生物制药公司，专注于开发用于治疗各种疾病的治疗性单克隆抗体和双特异性抗体。其药物候选者包括用于治疗炎症、过敏、自身免疫和其他严重疾病的抗体基础治疗。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更喜欢的五只股票比 Celldex Therapeutics 更好</li>
<li>一些最佳的大盘股有哪些？</li>
<li>半导体超级周期：为什么 Onsemi 股票可能会随着 AI 和电动车的增长而翻倍</li>
<li>如何从成长投资中获利</li>
<li>感恩节的最佳本地肉铺 [2025 调查]</li>
<li>为什么这些公司被认为是蓝筹股？</li>
<li>1.34 亿美元的内部交易：这对 KMI、ISRG 和 QS 可能意味着什么</li>
</ul>
<p><strong>想看看其他对 CLDX 持有股份的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取 Celldex Therapeutics, Inc.（NASDAQ:CLDX - 免费报告）的最新 13F 文件和内部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0xEWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0xEWA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Celldex Therapeutics 吗？</h2>
<p>在考虑 Celldex Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前... 而 Celldex Therapeutics 并不在名单上。</p>
<p>虽然 Celldex Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得买入。</p>
<p>查看这五只股票</p>

塞德斯医疗

<p>Y Intercept Hong Kong Ltd 在第二季度收购了 Celldex Therapeutics, Inc.（NASDAQ:CLDX）的新头寸，购买了 58,398 股，价值约为 119 万美元。其他机构投资者也调整了他们在该公司的持股。分析师为 CLDX 设定了不同的目标价格，普遍评级为 “适度买入”，平均目标价格为 44.20 美元。该股票已下跌 7.4%，开盘价为 24.75 美元，市值为 16.4 亿美元，市盈率为-8.22</p>

<p>Y Intercept Hong Kong Ltd bought a new position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) during the second quarter, according to its most recent 13F filing with the Securities &amp; Exchange Commission. The fund bought 58,398 shares of the biopharmaceutical company's stock, valued at approximately $1,188,000. Y Intercept Hong Kong Ltd owned about 0.09% of Celldex Therapeutics at the end of the most recent quarter.</p>
<div class="lb-trans"><p>Y Intercept Hong Kong Ltd 在第二季度根据其最新的 13F 文件向证券交易委员会报告，购买了 Celldex Therapeutics, Inc.（NASDAQ:CLDX - 免费报告）的新股份。该基金购买了 58,398 股生物制药公司的股票，价值约为 1,188,000 美元。Y Intercept Hong Kong Ltd 在最近一个季度末持有 Celldex Therapeutics 约 0.09% 的股份。</p>
</div><p>Get <strong>Celldex Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Celldex Therapeutics</strong> 的提醒：</p>
</div><p>A number of other institutional investors have also added to or reduced their stakes in the company. Envestnet Asset Management Inc. acquired a new position in Celldex Therapeutics during the second quarter worth $861,000. Nisa Investment Advisors LLC increased its holdings in shares of Celldex Therapeutics by 171.7% in the second quarter. Nisa Investment Advisors LLC now owns 1,394 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 881 shares during the last quarter. AlphaQuest LLC increased its holdings in shares of Celldex Therapeutics by 7.0% in the second quarter. AlphaQuest LLC now owns 12,956 shares of the biopharmaceutical company's stock valued at $264,000 after purchasing an additional 844 shares during the last quarter. TD Asset Management Inc increased its holdings in shares of Celldex Therapeutics by 62.1% in the second quarter. TD Asset Management Inc now owns 127,878 shares of the biopharmaceutical company's stock valued at $2,602,000 after purchasing an additional 49,000 shares during the last quarter. Finally, Sovran Advisors LLC bought a new stake in shares of Celldex Therapeutics in the second quarter valued at about $842,000.</p>
<div class="lb-trans"><p>其他一些机构投资者也增加或减少了对该公司的持股。Envestnet Asset Management Inc. 在第二季度收购了价值 861,000 美元的 Celldex Therapeutics 新股份。Nisa Investment Advisors LLC 在第二季度将其在 Celldex Therapeutics 的持股增加了 171.7%。Nisa Investment Advisors LLC 现在拥有 1,394 股生物制药公司的股票，价值 28,000 美元，此前在上个季度购买了额外的 881 股。AlphaQuest LLC 在第二季度将其在 Celldex Therapeutics 的持股增加了 7.0%。AlphaQuest LLC 现在拥有 12,956 股生物制药公司的股票，价值 264,000 美元，此前在上个季度购买了额外的 844 股。TD Asset Management Inc 在第二季度将其在 Celldex Therapeutics 的持股增加了 62.1%。TD Asset Management Inc 现在拥有 127,878 股生物制药公司的股票，价值 2,602,000 美元，此前在上个季度购买了额外的 49,000 股。最后，Sovran Advisors LLC 在第二季度购买了价值约 842,000 美元的 Celldex Therapeutics 新股份。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>A number of brokerages have recently issued reports on CLDX. Barclays assumed coverage on shares of Celldex Therapeutics in a research report on Monday, October 13th. They issued an &#34;underweight&#34; rating and a $25.00 target price for the company. HC Wainwright dropped their target price on shares of Celldex Therapeutics from $50.00 to $42.00 and set a &#34;buy&#34; rating for the company in a report on Wednesday, August 20th. Citigroup dropped their target price on shares of Celldex Therapeutics from $56.00 to $48.00 and set a &#34;buy&#34; rating for the company in a report on Wednesday, August 20th. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Celldex Therapeutics in a research note on Wednesday, October 8th. Finally, Wells Fargo &amp; Company lowered their price objective on Celldex Therapeutics from $44.00 to $38.00 and set an &#34;overweight&#34; rating for the company in a research note on Wednesday, August 20th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $44.20.</p>
<div class="lb-trans"><p>一些券商最近对 CLDX 发布了报告。巴克莱在 10 月 13 日星期一的研究报告中对 Celldex Therapeutics 的股票进行了覆盖，给予了 &#34;减持&#34; 评级和 25.00 美元的目标价。HC Wainwright 在 8 月 20 日星期三的报告中将 Celldex Therapeutics 的目标价从 50.00 美元下调至 42.00 美元，并给予了 &#34;买入&#34; 评级。花旗在 8 月 20 日星期三的报告中将 Celldex Therapeutics 的目标价从 56.00 美元下调至 48.00 美元，并给予了 &#34;买入&#34; 评级。Weiss Ratings 在 10 月 8 日星期三的研究报告中重申了对 Celldex Therapeutics 的 &#34;卖出（d-）&#34; 评级。最后，富国银行在 8 月 20 日星期三的研究报告中将 Celldex Therapeutics 的目标价从 44.00 美元下调至 38.00 美元，并给予了 &#34;增持&#34; 评级。一位股票研究分析师对该股票给予了强烈买入评级，七位分析师给予了买入评级，一位分析师给予了持有评级，两位分析师给予了卖出评级。根据 MarketBeat.com 的数据，该股票的共识评级为 &#34;适度买入&#34;，平均目标价为 44.20 美元。</p>
</div><p><strong>Check Out Our Latest Analysis on CLDX</strong></p>
<div class="lb-trans"><p><strong>查看我们对 CLDX 的最新分析</strong></p>
</div><h2>Celldex Therapeutics Stock Down 7.4%</h2>
<div class="lb-trans"><h2>Celldex Therapeutics 股票下跌 7.4%</h2>
</div><p>Shares of CLDX opened at $24.75 on Tuesday. Celldex Therapeutics, Inc. has a 12-month low of $14.40 and a 12-month high of $29.05. The business's fifty day moving average is $25.32 and its 200 day moving average is $22.62. The stock has a market cap of $1.64 billion, a P/E ratio of -8.22 and a beta of 1.33.</p>
<div class="lb-trans"><p>CLDX 的股票在星期二开盘价为 24.75 美元。Celldex Therapeutics, Inc. 的 12 个月低点为 14.40 美元，12 个月高点为 29.05 美元。该公司的 50 天移动平均线为 25.32 美元，200 天移动平均线为 22.62 美元。该股票的市值为 16.4 亿美元，市盈率为 -8.22，贝塔值为 1.33。</p>
</div><p>Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last issued its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.85) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.86) by $0.01. The company had revenue of $0.73 million for the quarter, compared to analysts' expectations of $1.13 million. Celldex Therapeutics had a negative return on equity of 27.61% and a negative net margin of 3,446.88%. On average, analysts expect that Celldex Therapeutics, Inc. will post -2.48 EPS for the current year.</p>
<div class="lb-trans"><p>Celldex Therapeutics（NASDAQ:CLDX - 获取免费报告）最近在 8 月 7 日星期四发布了其财报。这家生物制药公司报告的每股收益（EPS）为 -0.85 美元，超过了分析师的共识预期（-0.86 美元）0.01 美元。该公司在本季度的收入为 73 万美元，而分析师的预期为 113 万美元。Celldex Therapeutics 的股本回报率为 -27.61%，净利润率为 -3,446.88%。分析师预计 Celldex Therapeutics, Inc. 在本年度将发布 -2.48 的每股收益。</p>
</div><h2>About Celldex Therapeutics</h2>
<div class="lb-trans"><h2>关于 Celldex Therapeutics</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.</p>
<div class="lb-trans"><p>Celldex Therapeutics, Inc. 是一家生物制药公司，专注于开发用于治疗各种疾病的治疗性单克隆抗体和双特异性抗体。其药物候选者包括用于治疗炎症、过敏、自身免疫和其他严重疾病的抗体基础治疗。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Celldex Therapeutics</li>
<li>What Are Some of the Best Large-Cap Stocks to Buy?</li>
<li>Semiconductor Supercycle: Why Onsemi Stock Could Double as AI and EV Growth Accelerate</li>
<li>How to Profit From Growth Investing</li>
<li>The Best Local Butchers for Thanksgiving [2025 Survey]</li>
<li>Why Are These Companies Considered Blue Chips?</li>
<li>$134M in Insider Moves: What It Might Mean for KMI, ISRG and QS</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更喜欢的五只股票比 Celldex Therapeutics 更好</li>
<li>一些最佳的大盘股有哪些？</li>
<li>半导体超级周期：为什么 Onsemi 股票可能会随着 AI 和电动车的增长而翻倍</li>
<li>如何从成长投资中获利</li>
<li>感恩节的最佳本地肉铺 [2025 调查]</li>
<li>为什么这些公司被认为是蓝筹股？</li>
<li>1.34 亿美元的内部交易：这对 KMI、ISRG 和 QS 可能意味着什么</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding CLDX?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对 CLDX 持有股份的对冲基金吗？</strong> 访问 HoldingsChannel.com 获取 Celldex Therapeutics, Inc.（NASDAQ:CLDX - 免费报告）的最新 13F 文件和内部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0xEWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=CLDX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Celldex Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Celldex Therapeutics 吗？</h2>
</div><p>Before you consider Celldex Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Celldex Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celldex Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前... 而 Celldex Therapeutics 并不在名单上。</p>
</div><p>While Celldex Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Celldex Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得买入。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Y Intercept Hong Kong Ltd 在塞德斯医疗公司（Celldex Therapeutics, Inc.）中建立了价值 119 万美元的头寸